Pharmaceutical Industry and Manufacturers of Medical Products

Reimbursement and Market Access

The structures of our health system are becoming more and more complex. Budgetary constraints entail restrictions. Market access is becoming more and more difficult within a challenging pharmapolitical context in which innovations are not appropriately appreciated.

ECHOconsult helps you to develop strategies and realize concrete projects in order to achieve an optimal market position for your products within this environment.

According to international reimbursement requirements and especially due to German Pharmaceutical Market Restructuring Act (AMNOG) it is absolutely essential to have evidence of added value. This value is only proven for the innovation when

there is a necessity ("medical need"),
the "added value" is evidence-based
the patients who have the highest benefit ("target population") are known
the additional costs ("budgetary impact") are defined for the payers [statutory health insurance scheme]

ECHOconsult offers highly qualified advice on the evaluation of the benefit as a basis for the development of successful market access strategies for your products.

The service of ECHOconsult